All In Biotech

Drug Trial Radar · NCT07949344

A Post-Marketing Trial to Evaluate the Safety and Efficacy of Quizartinib in Chinese Participants With Newly Diagnosed FMS-like Tyrosine Kinase 3-internal Tandem Duplication [FLT3-ITD] (+) Acute Myeloid Leukemia (AML)

A Phase 4, Open-label, Single-arm, Interventional Trial Evaluating Safety and Efficacy of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in Chinese Participants 18 to 75 Years Old With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia

Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Dec 1, 2026

Primary completion

Jun 30, 2030

Study completion Jun 30, 2030

Sponsor

Sponsor type
Industry
First posted
Nov 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The clinical trial is designed to assess the safety of quizartinib in newly diagnosed FLT3-ITD (+) AML in Chinese participants.

Conditions

  • Acute Myeloid Leukemia

Interventions

  • QuizartinibDrug

    Participants will receive quizartinib 40 mg orally once daily for 14 days during the induction and consolidation phases and 30 mg orally once daily, increased to 60 mg once daily in the maintenance phase.

  • ChemotherapyDrug

    Participants will receive commercially available cytarabine (cytosine arabinoside) and anthracycline (daunorubicin or idarubicin).

  • Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)Genetic

    Allogeneic HSCT is one of the options for consolidation therapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Grade Greater than or Equal to (≥)3 Treatment-Related Adverse Events (TRAEs)Time frame: Up to approximately 39 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.